All In Biotech

Drug Trial Radar · NCT04734197

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: May 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 349 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

349

Actual

Start

Jan 11, 2021

Primary completion

Mar 25, 2022

Study completion Mar 25, 2022

Sponsor

Lead sponsor
Surface Ophthalmics, Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop. The purpose of this research study is to see how well SURF-100 works to treat dry eye and what potential side effects there are, and to compare it with Vehicle (placebo), 0.1% mycophenolic acid (MPA) in Vehicle, 0.3% MPA in Vehicle, 0.01% betamethasone phosphate (BSP) in Vehicle, Restasis and Xiidra. This study will involve about 280-350 study participants age 18 and older at about 40 different research sites in the United States.

Conditions

  • Dry Eye Disease

Interventions

  • SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)Drug

    combination of a topical immunosuppressant and a topical corticosteroid solution

  • Mycophenolic Acid 0.1%Drug

    topical immunosuppressant

  • Mycophenolic Acid 0.3%Drug

    topical immunosuppressant

  • Betamethasone Sodium Phosphate 0.01%Drug

    topical corticosteroid solution

  • Placebo Comparator: VehicleDrug

    topical vehicle solution

  • Cyclosporine 0.05% Ophthalmic EmulsionDrug

    topical ophthalmic emulsion

  • Lifitegrast 5% Ophthalmic SolutionDrug

    topical ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder AnalysisTime frame: Baseline and Day 84

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Cornea and Cataract Consultants of Arizona PC

    Phoenix, Arizona

  • Canyon City EyeCare

    Azusa, California

  • Inland Eye Specialists

    Hemet, California

  • North Valley Eye Medical Group Inc.

    Mission Hills, California

  • LoBue Laser and Eye Medical Center

    Murrieta, California

  • Eye Research Foundation

    Newport Beach, California

  • Martel Eye Medical Group

    Rancho Cordova, California

  • Sacramento Eye Consultants, A Medical Corporation

    Sacramento, California

  • The Eye Center of Northern Colorado

    Fort Collins, Colorado

  • Connecticut Eye Consultants, PC

    Danbury, Connecticut

  • Florida Eye Microsurgical Institute, Inc.

    Boynton Beach, Florida

  • Hernando Eye Institute

    Brooksville, Florida

  • Bowden Eye and Associates

    Jacksonville, Florida

  • Eye Center of North Florida PA

    Panama City, Florida

  • International Research Center

    Tampa, Florida

  • Blue Ocean Clinical Research at The Macula Center

    The Villages, Florida

  • Coastal Research Associates, LLC

    Roswell, Georgia

  • Jackson Eye

    Lake Villa, Illinois

  • Cincinnati Eye Institute

    Edgewood, Kentucky

  • Kentucky Eye Institute

    Lexington, Kentucky

  • Midwest Vision Research Foundation at Pepose Vision Institute

    Chesterfield, Missouri

  • Tauber Eye Center

    Kansas City, Missouri

  • Tekwani Vision Center

    St Louis, Missouri

  • Ophthalmology Consultants Ltd.

    St Louis, Missouri

  • EyeSight Ophthalmic Services

    Somersworth, New Hampshire

  • Alterman, Modi & Wolter

    Poughkeepsie, New York

  • Rochester Ophthalmological Group, PC

    Rochester, New York

  • Physicians Protocol

    Greensboro, North Carolina

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota

  • Total Eye Care, PA

    Memphis, Tennessee

  • VRF Eye Specialty Group

    Memphis, Tennessee

  • West TN EyeCare dba Toyos Clinic

    Nashville, Tennessee

  • Texan Eye Care, PA - Keystone Research, Ltd

    Austin, Texas

  • Houston Eye Associates

    Houston, Texas

  • Advanced Laser Vision & Surgical Institute

    Houston, Texas

  • Eye Clinics of South Texas, PA

    San Antonio, Texas

  • R and R Eye Research, LLC

    San Antonio, Texas

  • Tanner Clinic

    Layton, Utah

  • The Eye Institute of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.